Opening up about patient engagement
November 9, 2021 | patient engagement
Read the third blog of the series looking at key barriers to effective patient engagement in pharma
Inspired by this year’s Patient Centricity and Engagement Conference, Philippa Pristerà uses this mini blog series to reflect on key barriers to patient engagement raised during the event, and share tips and guidance on how to overcome them, collated from her own experience and those shared by speakers from the day.
Opening up about patient engagement
Two patient advocates who spoke at the conference both described pharma as “secretive”. It seemed to stem from the lack of transparency and communication around how and when they would be engaged, and when they couldn’t be. One had recently been stopped from attending a conference tailored for healthcare providers, but no one explained to her why.
This kind of ‘blocking’ can create a feeling of secrecy and depreciates industry messages that they see ‘patients as partners’. She also made the brilliant point that pharma companies do very little to communicate the fact that patients can get involved with their work – “I see the good side of pharma, but you don’t show it!”.
Health research organisations, academic research centres and charities make ‘How to get involved’ a prominent statement on their websites. But pharma companies don’t often showcase the breadth and depth of their patient engagement activity to the public and do even less to provide easy paths for other people to get involved. There are challenges at all stages of research and medicine development, but so few of them get voiced to patient groups to help solve them.
Regulations within the pharma industry may make it difficult to maintain an open dialogue at every step of a medicine’s development. But, encouraging regular communication with patients and being open about where R&D is at, and the shared challenges that exist could be adopted by all.
Fix it by…
- Shouting about your patient engagement. You do more than people know, so open up and be transparent about the engagement activity that is going on
- Creating opportunities for people to get involved in an open and inclusive way. Let people know what issues you are facing and how they can help
- Committing time and resource to frequent communication. This includes sharing more about your research activity and issues you face, sending regular updates for shared projects, and providing a continued point of contact for ad hoc check-ups
- Providing feedback on the project so patients know their contribution makes a difference. This makes them feel valued, demonstrates a company’s commitment to act on their insights, and reinforces positive feelings that will make them more likely to engage with future work and even inspire others to do the same
Missed a post in the series? Catch-up here:
In need of further guidance?
- The Patient Focused Medicines Development team have recently launched a new quality framework that can be used as both a planning tool and assessment tool to ensure you are carrying out high-quality, meaningful engagement.
- For something less focused on medicine development or medtech, check out the UK Standards for Public Involvement, which were co-produced by a UK-wide partnership to improve the quality and consistency of public involvement in research.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
How to boost clinical trial access and make patients health-empowered
Clinical research is becoming more patient-centric, but there’s still more that needs to be done to make clinical trials available to everyone. This could include wider participation.
Closing the loop: Why clinical trial results matter to participants
Discover why sharing clinical trial results with participants is crucial for respect, informed health decisions, and fostering strong researcher-participant partnerships.
Unveiling the truth: A journey into women’s representation in clinical trials
We explore the historical exclusion of women from clinical trials, its consequences on medical research and treatment efficacy and the ongoing efforts to ensure their representation.
Clarity in clinical trials
Discover how transparent, empathetic communication and health literacy principles can empower patients and enhance engagement in clinical trials, transforming participants into active partners in their healthcare journey.
Caring for patients’ mental health in clinical trials
We look at why ensuring continuous mental health support for patients in clinical trials is essential to enhance their overall well-being and trial engagement.
Driving equitable healthcare: The role of DE&I in clinical trials
Diversity, equity and inclusion (DE&I) is becoming a bigger topic of conversation and meaningful action within clinical trials. And for good reason, too. Find out why we embrace this and…
Empowering patients through more accessible clinical trial information
Senior Medical Writer, Scott Palmer explores the challenges and solutions in enhancing patient engagement in clinical trials, from the pivotal role of healthcare professionals, to the importance of user-friendly trial…
New report now available: Integrating ‘patient first’ into medicine development
A new report has just been published by Cuttsy+Cuttsy that collates all the current best thinking in the ‘patient first’ space, distilling it into a practical and actionable road map…
The digital prescription – enhancing the patient experience with technology
We explore how digital health innovations are revolutionising patient care by enhancing accessibility, personalisation, and engagement, promising a more connected and empowered patient experience.
Compliance — a driving force for influencing public perceptions of the pharma industry?
How does compliance play into public perceptions of pharma and why is it important for improving public opinion?